past
two
decad
numer
attempt
use
anim
order
produc
recombin
human
protein
monoclon
antibodi
howev
recent
first
two
therapeut
agent
isol
milk
transgen
anim
inhibitor
ruconest
antithrombin
atryn
appear
market
inspir
hope
consider
number
new
recombin
protein
creat
use
technolog
could
becom
avail
practic
use
near
futur
review
method
appli
produc
transgen
anim
describ
advantag
drawback
relat
use
produc
recombin
human
protein
monoclon
antibodi
discuss
success
express
first
recombin
protein
rp
bacteria
yeast
becam
clear
larg
number
human
rp
could
effici
produc
use
system
thu
human
protein
undergo
posttransl
modif
bacteri
cell
natur
modif
yeast
cell
differ
take
place
human
cell
addit
express
system
ensur
proper
fold
number
complex
human
rp
therefor
research
commun
face
challeng
develop
altern
express
system
capabl
ensur
correct
posttransl
modif
rp
simultan
develop
two
technolog
model
base
transgen
anim
mammalian
cell
cultur
start
result
first
success
product
transgen
mammal
microinject
genet
engin
construct
pronucleu
mous
zygot
carri
year
ago
larg
number
transgen
anim
ta
produc
sinc
scientif
purpos
improv
livestock
produc
rp
end
past
centuri
ta
consid
promis
model
produc
human
rp
monoclon
antibodi
mab
yet
mammalian
cell
cultur
chines
hamster
ovari
cell
cho
particular
play
domin
role
product
rp
thu
therapeut
product
obtain
use
live
organ
introduc
us
market
total
product
obtain
use
mammalian
cell
cultur
produc
use
cho
cell
cultur
larg
attribut
fact
european
medicin
evalu
agenc
emea
approv
antithrombin
first
recombin
protein
deriv
milk
transgen
goat
protein
subsequ
approv
commerci
unit
state
food
drug
administr
fda
drug
prevent
blood
clot
patient
hereditari
antithrombin
defici
emea
approv
use
recombin
inhibitor
produc
rabbit
treatment
hereditari
angioedema
arriv
market
first
therapeut
product
produc
use
ta
approv
medic
use
suggest
rp
could
carv
signific
nich
biotechnolog
near
futur
biotechnolreview
ogi
compani
ppl
therapeut
england
gtc
biotherapeut
usa
acquir
lfb
biotechnolog
franc
hematech
usa
genzym
usa
zymogenet
usa
nexia
biotechnolog
canada
pharm
netherland
bioprotein
technolog
franc
avigen
usa
viragen
usa
tranxenogen
usa
activ
work
develop
technolog
review
discuss
gener
concept
behind
gener
ta
product
human
rp
mab
contemporari
method
allow
one
obtain
rpproduc
livestock
contain
requir
transgen
cell
organ
pass
offspr
includ
intrapronuclear
zygot
dna
microinject
mi
somat
cell
nuclear
transfer
nt
today
dna
microinject
male
pronucleu
zygot
commonli
use
method
fig
enter
nucleu
linear
dna
capabl
integr
genom
cell
line
live
organ
dna
usual
integr
transcript
inact
genepoor
region
heterochromatin
one
sever
even
hundr
copi
inject
construct
integr
one
genom
site
technolog
initi
test
mice
remain
reliabl
method
product
ta
method
use
produc
first
agricultur
ta
howev
mi
use
mainli
produc
transgen
mice
rabbit
pig
attribut
insuffici
effici
method
due
low
frequenc
incorpor
recombin
dna
genom
avail
zygot
two
pronuclear
stage
result
depend
carri
larg
number
surgic
procedur
entail
need
keep
substanti
number
head
experiment
livestock
perform
skill
anim
handl
furthermor
way
determin
express
level
integr
transgen
examin
origin
ta
offspr
reproduct
cycl
larg
anim
includ
time
reach
physiolog
matur
need
obtain
femal
produc
rp
milk
origin
transgen
male
approxim
year
goat
femalesmal
year
pig
year
cow
limit
increas
cost
obtain
origin
ta
time
requir
organ
work
sheep
clone
produc
nuclear
transfer
nt
somat
mammari
gland
cell
oocyt
achiev
open
possibl
develop
cheaper
easier
procedur
produc
agricultur
ta
fig
sinc
manipul
case
move
farm
laboratori
transfect
somat
cell
carri
clone
character
integr
transgen
genom
select
nucleu
somat
cell
inject
enucl
oocyt
transplant
femal
recipi
fibroblast
cell
typic
use
nt
major
recent
gener
larg
farm
anim
obtain
nt
howev
transfect
cell
case
select
use
antibiot
resist
marker
review
gene
complic
approv
produc
recombin
protein
fda
emea
fluoresc
protein
enhanc
green
fluoresc
protein
egfp
often
use
addit
select
agent
order
increas
effici
select
system
base
sitespecif
recombinas
addit
use
remov
select
marker
genom
select
cell
line
advers
effect
nt
techniqu
includ
low
utero
embryo
surviv
rate
poor
health
newborn
anim
attribut
among
thing
incomplet
reprogram
somat
nucleu
result
impair
express
sever
gene
requir
proper
progress
embryogenesi
moreov
process
obtain
suitabl
oocyt
activ
requir
consider
expenditur
time
financi
resourc
result
one
world
leader
use
nt
product
agricultur
ta
agroresearch
compani
new
zealand
reject
method
compani
develop
altern
method
produc
agricultur
ta
sitespecif
transgenesi
technolog
use
embryon
stem
es
cell
could
altern
mi
nt
method
method
involv
insert
transgen
genom
es
cell
follow
select
clone
proper
integr
requir
number
copi
transgen
es
cell
introduc
caviti
blastocyst
transplant
recipi
femal
cell
transplant
ovari
adult
mice
newborn
mice
carri
transgen
anim
handl
perform
use
nonsurg
method
wide
use
anim
husbandri
product
transgen
requir
rel
small
number
blastocyst
henc
small
experiment
herd
howev
method
perfect
mice
rat
es
cell
line
farm
anim
yet
obtain
similar
approach
involv
transform
stem
cell
precursor
sperm
cell
subsequ
transplant
seminifer
tubul
infertil
male
method
obtain
ta
rel
rare
use
thu
ta
effect
produc
use
retrovirus
contain
requir
transgen
order
achiev
object
zygot
lack
protect
coat
cultur
medium
supplement
lentivir
particl
follow
transplant
femal
recipi
integr
one
sever
copi
transgen
occur
depend
lentivir
titer
almost
offspr
transgen
case
advantag
method
includ
effici
product
speci
ta
opportun
produc
ta
carri
one
transgen
copi
sometim
necessari
scientif
purpos
main
drawback
method
includ
inabl
use
intron
present
gene
construct
limit
transgen
length
approxim
bp
determin
size
viral
particl
result
difficult
achiev
high
level
transgen
express
use
method
promis
method
obtain
ta
use
vector
base
mobil
genet
element
integr
genom
transposas
gene
encod
transposas
transgen
flank
termin
repeat
transposon
coinject
zygot
reaction
catalyz
transposas
result
integr
singl
copi
transgen
one
sever
site
anim
genom
approach
use
produc
larg
farm
anim
eg
pig
effici
integr
transgen
case
depend
type
transposon
transgen
length
concentr
site
dna
inject
high
howev
data
regard
level
express
target
gene
ta
produc
use
method
obtain
thu
far
group
method
base
infect
organ
tissu
organ
replicationdefect
adenoviru
contain
gene
target
protein
specif
mention
approach
result
shortterm
nonhereditari
product
rp
organ
tissu
consider
today
remain
difficult
compar
effici
new
tradit
method
produc
ta
express
vector
use
produc
rp
milk
contain
regulatori
region
gene
whose
protein
product
compris
major
fraction
milk
popular
exampl
latter
includ
regulatori
region
lactoglobulin
sheep
gene
acid
protein
gene
rodent
mous
rat
rabbit
gene
cow
goat
gene
express
vector
typic
includ
long
kb
consist
promot
tissuespecif
enhanc
increas
express
mammari
gland
first
noncod
exon
intron
locat
fig
first
intron
gene
like
contain
regulatori
element
enhanc
gene
transcript
express
vector
also
includ
region
utr
gene
whose
size
vari
kb
even
typic
includ
last
noncod
exon
intron
polyadenylareview
tion
site
adjac
sequenc
potenti
enhanc
transcript
termin
vector
may
belong
either
one
differ
gene
among
promot
use
express
mammari
gland
gene
promot
one
effici
use
product
target
protein
mammari
gland
mice
goat
cow
tabl
popular
commerci
vector
product
rp
milk
ta
invitrogen
produc
use
aforement
promot
fig
vector
allow
one
obtain
transgen
goat
line
character
high
level
target
protein
product
regulatori
region
gene
length
kb
consist
promot
hormonedepend
enhanc
stimul
promot
mammari
gland
cell
use
vector
structur
vector
also
includ
gene
ensur
effici
transcript
termin
latter
requir
format
stabl
mrna
encod
target
protein
prevent
transcript
adjac
genom
region
capabl
caus
format
repress
chromatin
rna
interfer
order
accumul
target
protein
milk
code
region
gene
must
contain
signal
peptid
sequenc
requir
secret
sequenc
obtain
gene
encod
secret
protein
depend
aim
either
complet
gene
intron
cdna
minigen
contain
intron
insert
vector
use
gene
unmodifi
exonintron
structur
allow
one
obtain
much
higher
level
target
protein
product
ta
comparison
use
cdna
instanc
human
lactoferrin
gene
express
use
vector
sever
independ
studi
fig
concentr
recombin
lactoferrin
exceed
mgml
mous
milk
mgml
transgen
goat
milk
cdna
use
produc
ta
tabl
transgen
mice
produc
use
nativ
lactoferrin
gene
intron
kb
long
concentr
recombin
lactoferrin
milk
high
mgml
tabl
transgen
goat
carri
one
copi
construct
express
mgml
recombin
human
lactoferrin
milk
also
produc
differ
express
recombin
lactoferrin
use
promot
cow
similar
tabl
exampl
demonstr
presenc
intron
code
region
transgen
result
twofold
increas
amount
target
protein
milk
site
construct
integr
genom
play
crucial
role
ensur
effici
transgen
express
inject
dna
typic
incorpor
genepoor
region
character
frequent
dna
break
chromatin
region
typic
exert
neg
influenc
express
transgen
integr
nearbi
addit
sever
copi
construct
typic
integr
onto
genom
site
turn
lead
repress
transcript
due
format
heterochromatin
repetit
sequenc
number
regulatori
element
use
protect
transgen
express
repress
maintain
direct
relationship
number
copi
level
transgen
express
mammalian
cell
cultur
atrich
region
dna
bind
nuclear
matrix
fraction
known
marsarel
regulatori
element
uco
activ
promot
household
gene
starel
block
spread
heterochromatin
insul
among
mention
regulatori
element
insul
use
vector
construct
produc
ta
insul
regulatori
element
block
interact
enhanc
promot
locat
moreov
insul
act
boundari
transcript
activ
chromatin
heterochromatin
insul
cluster
chicken
gene
insul
one
intens
studi
vertebr
insul
bp
long
locat
locu
core
region
character
full
insul
activ
found
segment
contain
bind
site
ctcf
protein
character
vertebr
insul
protein
ctcf
protein
respons
abil
insul
block
enhanc
also
assist
protein
form
boundari
activ
chromatin
heterochromatin
bind
insul
insul
sequenc
also
bind
protein
protect
gcrich
sequenc
insul
methyl
lead
disrupt
bind
insul
protein
dna
result
inactiv
insul
accord
exist
model
also
termin
weak
transcript
initi
heterochromat
region
play
import
role
protect
locu
propag
inact
chromatin
vector
construct
invitrogen
usa
ta
product
contain
two
copi
insul
vector
fig
promot
goat
insul
pignt
cow
goatmi
cow
mousemi
nativ
gene
bacmid
cownt
review
thorough
analysi
effect
insul
transcript
activ
sever
promot
includ
goat
promot
rabbit
wappromot
demonstr
insul
significantli
increas
level
transgen
express
number
transgen
line
character
signific
product
target
protein
meanwhil
insul
neither
affect
variabl
transgen
express
ectop
express
tissu
organ
ensur
direct
correl
number
transgen
copi
level
express
thu
insul
act
univers
transcript
regul
use
increas
activ
weak
promot
howev
allow
achiev
effici
transgen
express
exclus
mammari
gland
import
product
mani
target
protein
advers
affect
health
ta
increas
size
regulatori
sequenc
transgen
construct
altern
insul
regulatori
element
multipl
loci
express
milk
protein
gene
possess
extend
contain
tissuespecif
enhanc
insul
capabl
provid
protect
influenc
adjac
gene
instanc
construct
synthes
code
region
kb
mous
wap
gene
consist
kb
replac
structur
part
human
lactoferrin
gene
kb
result
transgen
mice
obtain
whose
mammari
gland
character
high
tissuespecif
transgen
express
product
recombin
human
lactoferrin
milk
high
mgml
tabl
anoth
method
obtain
ta
effici
produc
target
protein
integr
larg
dna
segment
kb
genom
vector
base
bacteri
artifici
chromosom
bacmid
enabl
clone
sequenc
kb
long
use
prepar
extend
gene
construct
regulatori
region
tissuespecif
gene
occupi
larg
genom
region
part
neighbor
gene
exampl
sever
enhanc
stimul
pig
wap
gene
found
kb
away
gene
regul
separ
gene
larg
dna
fragment
use
highli
like
regulatori
element
gene
includ
transgen
assum
use
approach
result
specif
transgen
express
exclus
mammari
gland
influenc
surround
chromatin
transgen
express
minim
approach
allow
one
obtain
ta
whose
level
transgen
express
close
correspond
express
endogen
counterpart
instanc
transgen
cow
express
gene
human
lactoferrin
human
produc
tabl
gener
method
allow
one
achiev
stabl
transgen
express
level
similar
nativ
gene
thu
level
product
lactoferrin
alphalactalbumin
transgen
cow
mgml
respect
tabl
problem
associ
gene
part
bacmid
structur
whose
express
advers
affect
health
ta
also
mention
use
bacmid
complet
suppress
effect
genom
surround
express
partial
depend
genom
integr
site
case
direct
observ
relationship
number
bacmid
copi
express
level
attribut
fact
initi
rna
interfer
advers
affect
gene
express
bacmid
sinc
earli
attempt
made
produc
ta
synthes
varieti
human
protein
today
protein
produc
express
system
bacteria
yeast
mammalian
cell
recombin
human
protein
produc
mammalian
cell
cultur
plasma
protein
use
recombin
plasma
protein
grow
everi
year
scope
applic
expand
use
human
tissu
isol
nativ
protein
constrain
exist
risk
viral
contamin
small
number
donor
ethic
consider
coagul
factor
vii
viii
ix
use
lifelong
treatment
hereditari
diseas
immun
respons
therapeut
agent
develop
patient
time
despit
highli
effici
purif
protein
produc
bacteri
yeast
system
fact
creat
need
replac
drug
analog
produc
differ
manner
therefor
product
recombin
coagul
factor
milk
ta
signific
medic
import
tabl
show
exampl
ta
whose
milk
contain
human
blood
clot
factor
treatment
blood
diseas
case
requir
compar
small
amount
calcul
gram
rp
consequ
rabbit
optim
ta
produc
rp
transgen
rabbit
femal
produc
approxim
liter
milk
per
lactat
g
rp
per
year
result
obtain
demonstr
express
coagul
factor
affect
anim
health
lactat
unlik
coagul
factor
vii
viii
ix
demand
recombin
albumin
calcul
ton
sinc
albumin
use
medicin
also
biotechnolog
stabil
protein
albumin
major
blood
protein
usual
isol
plasma
product
recombin
albumin
expens
isol
blood
plasma
sinc
high
degre
purif
requir
medic
applic
nowaday
recombin
albumin
produc
mostli
yeast
saccharomyc
cerevisia
recombumin
tm
pichia
pastori
albrec
tm
huge
demand
recombin
albumin
determin
choic
transgen
cow
product
thu
gtc
biotherapeut
usa
recent
creat
transgen
cow
whose
averag
level
recombin
human
albumin
rhab
product
milk
mgml
kg
per
produc
cow
per
year
work
describ
line
transgen
cow
whose
rha
concentr
milk
high
mgml
correspond
integr
copi
construct
transgen
cow
line
character
shorter
period
lactat
decreas
milk
yield
thu
assum
product
rhab
milk
transgen
cow
must
mgml
certain
protein
hormon
cytokin
neg
effect
lactat
health
ta
make
mainten
transgen
herd
problemat
notabl
project
undertaken
pharmathen
inc
compani
usa
instruct
ministri
defens
connect
product
butyrylcholinesteras
tabl
highli
activ
enzym
effici
protect
organophosph
poison
result
herd
goat
produc
whose
level
product
recombin
human
butyrylcholinesteras
rhbche
milk
mgml
main
problem
compani
en
coagul
factor
viii
cdna
wappromot
mous
rabbitmi
review
counter
effect
rhbche
lactat
latter
significantli
reduc
product
transgen
goat
result
question
regard
econom
feasibl
use
transgen
goat
obtain
rhbche
arisen
sever
approach
allow
one
produc
rp
advers
affect
lactat
health
ta
howev
resolv
problem
partial
first
promot
stabli
function
mammari
gland
rel
low
level
select
instanc
recombin
human
granulocyt
coloni
stimul
factor
rhgcsf
produc
use
gene
promot
without
enhanc
transgen
goat
tabl
howev
rhgcsf
concentr
milk
goat
exceed
mgml
transgen
mice
milk
contain
mgml
rhgcsf
also
produc
express
vector
contain
region
gene
goat
bp
includ
first
intron
gene
cow
bp
noncod
exon
also
use
result
demonstr
transgen
mice
carri
vector
express
rhgcsf
exclus
milk
tissu
howev
low
level
rp
milk
reduc
econom
attract
approach
altern
way
produc
rp
advers
affect
health
produc
ta
infect
mammari
gland
replicationdefect
vector
base
adenovirus
thu
adenovir
vector
design
express
recombin
human
erythropoietin
produc
laboratori
transgenesi
anim
clone
havana
cuba
erythropoietin
concentr
milk
goat
infect
adenoviru
reach
mgml
exhibit
low
biolog
activ
presum
due
insuffici
glycosyl
protein
produc
use
approach
product
recombin
human
growth
hormon
mice
mgml
goat
mgml
use
adenovir
vector
describ
similar
approach
use
case
recombin
human
lactoferrin
whose
concentr
milk
goat
high
mgml
despit
simplic
use
anim
adenovir
vector
creat
ta
express
target
protein
milk
method
allow
one
obtain
stabl
express
recombin
protein
level
suffici
commerci
product
high
express
level
mgml
observ
exclus
first
day
lactat
explain
either
natur
death
transfect
cell
immun
respons
infect
final
product
inact
form
protein
consid
promis
approach
instanc
express
vector
contain
erythropoietin
cdna
integr
fifth
exon
lactoglobulin
gene
cow
manner
region
cleavabl
igaproteas
code
region
two
gene
construct
order
produc
recombin
human
erythropoietin
result
transgen
mice
rabbit
produc
whose
milk
concentr
chimer
protein
reach
mgml
respect
follow
cleavag
chimer
protein
igaproteas
activ
erythropoietin
restor
lactat
health
ta
affect
also
possibl
use
coexpress
rp
inhibitor
block
activ
thu
recombin
human
prourokinas
express
milk
almost
immedi
transform
activ
form
urokinas
make
bioreactor
unpromis
respect
product
therapeut
form
protein
prourokinas
prourokinas
coexpress
bacteri
serin
proteas
inhibitor
milk
transgen
mice
order
resolv
problem
allow
purifi
milk
transgen
mice
process
prourokinas
urokinas
dramat
increas
yield
therapeut
form
protein
mention
sialyl
rp
milk
transgen
rabbit
pig
similar
sialyl
human
cell
essenti
reduc
immunogen
drug
use
longterm
therapi
incorrect
posttransl
modif
reduc
activ
recombin
protein
occur
milk
transgen
goat
cow
easiest
way
remov
incorrect
modif
mutat
protein
site
undesir
modif
occur
exampl
alphafetoprotein
singl
chain
glycosyl
plasma
protein
molecular
weight
kda
use
treat
autoimmun
diseas
demand
properli
fold
recombin
human
alphafetoprotein
rhafp
extrem
high
kilogram
protein
need
henc
merrimack
pharma
compani
usa
togeth
gtc
biotherapeut
usa
launch
project
product
transgen
goat
produc
rhafp
milk
human
alphafetoprotein
isol
milk
transgen
goat
glycosyl
asparagin
residu
locat
posit
greatli
reduc
activ
therefor
glutamin
residu
replac
asparagin
residu
rhafp
caus
inactiv
glycosyl
site
demonstr
biolog
activ
pharmacokinet
mutant
variant
alphafetoprotein
similar
nativ
protein
mab
market
fastest
grow
segment
pharmaceut
industri
therapeut
mab
use
treat
cancer
autoimmun
disml
milk
obtain
use
vector
tabl
howev
publish
data
express
level
mab
milk
transgen
goat
virtual
absent
transgen
goat
one
show
express
level
approach
mgml
mention
one
review
accord
data
provid
gtc
biotherapeut
compani
usa
mab
isol
milk
transgen
goat
typic
stabl
highli
effici
even
high
level
mab
express
affect
health
lactat
transgen
goat
compani
develop
rel
simpl
method
obtain
highli
purifi
mab
suitabl
medic
applic
conduct
investig
led
regard
transgen
goat
optim
model
product
mab
attract
transgen
goat
attribut
fact
rare
get
infect
bse
comparison
sheep
cow
transgen
goat
new
zealand
australia
current
use
product
rp
milk
sinc
offici
believ
cow
diseas
countri
demand
mab
recent
hit
severalhundredkilogramsperyear
mark
exampl
world
demand
antireceptor
mab
exce
kg
per
year
estim
herd
consist
transgen
goat
whose
milk
contain
mab
concentr
gl
fulli
meet
world
demand
mab
approxim
cost
meanwhil
l
cell
cultur
capac
approxim
cost
requir
obtain
equal
amount
mab
eas
gener
profit
billion
american
biotechnolog
compani
mab
current
use
medicin
produc
exclus
mammalian
cell
cultur
sinc
proper
posttransl
modif
requir
ensur
therapeut
effici
import
modif
includ
attach
oligosaccharid
sialic
acid
consider
increas
mab
bloodstream
circul
time
reduc
immunogen
howev
rp
produc
cell
cultur
rel
high
cost
henc
attempt
use
ta
produc
antibodi
made
end
sinc
mab
compos
two
polypeptid
chain
two
construct
contain
gene
encod
heavi
light
subunit
use
express
ta
produc
ta
sever
construct
encod
heavi
light
chain
antibodi
typic
incorpor
genom
site
initi
experi
mab
express
use
variou
gene
promot
milk
protein
eg
sheep
mous
wap
transgen
mice
whose
milk
contain
mab
rel
high
concentr
mgml
produc
result
tabl
mab
pharmaceut
product
subsequ
obtain
transgen
goat
mab
test
express
vector
evalu
qualiti
mab
refin
method
use
isol
obtain
transgen
mice
vector
describ
wide
use
express
mab
fig
highest
express
level
mab
transgen
mice
high
mg
antilewi
promot
goat
mousetwo
nativ
gene
antilewi
promot
goat
mousetwo
nativ
gene
promot
goat
insul
surfac
antigen
hepat
viru
promot
goat
insul
surfac
antigen
hepat
b
viru
review
despit
rel
low
cost
mab
product
transgen
goat
drawback
associ
use
comparison
use
mammalian
cell
cultur
firstli
antibodi
must
properli
glycosyl
sialyl
import
stabil
immunogen
biolog
activ
sialyl
glycosyl
occur
mammari
gland
transgen
goat
may
incomplet
addit
increas
level
mab
express
associ
decreas
glycosyl
effici
therefor
mgml
consid
optim
level
mab
milk
second
problem
associ
fact
sialic
acid
present
transgen
goat
form
nacetylneuramin
acid
nana
human
antibodi
contain
nglycolylneuramin
acid
ngna
possibl
antibodi
contain
wrong
sialic
acid
could
immunogen
patient
case
recombin
protein
mammalian
cell
cultur
also
undergo
heterogen
glycosyl
sialyl
process
usual
complet
ident
nativ
counterpart
order
overcom
hurdl
addit
gene
encod
transport
enzym
increas
level
glycosyl
sialyl
gene
whose
rnaproduct
induc
inactiv
gene
encod
protein
advers
affect
glycosyl
introduc
cell
line
produc
recombin
protein
opportun
inactiv
gene
involv
glycosyl
rp
cell
line
differ
glycosyl
human
cell
recent
becam
avail
due
develop
new
technolog
sitedirect
mutagenesi
similar
approach
use
produc
anim
sinc
chang
genom
advers
affect
viabil
ta
potenti
option
creat
ta
use
vector
strict
control
express
exclus
mammari
gland
vector
must
express
addit
gene
increasemodifi
glycosyl
gene
encod
group
rna
capabl
inactiv
gene
whose
protein
product
respons
abnorm
glycosyl
rp
final
presenc
approxim
mgml
endogen
immunoglobulin
goat
milk
pose
addit
problem
mab
purif
therefor
effici
chromatograph
separ
goat
human
immunoglobulin
requir
order
obtain
highli
purifi
mab
meanwhil
introduct
synthet
media
cultiv
cell
cultur
significantli
simplifi
stage
recombin
protein
purif
somewhat
reduc
cost
obtain
highli
purifi
mab
recent
demonstr
absenc
fucos
glycol
chain
antibodi
result
induct
cytotox
antibodi
concentr
ten
time
lower
case
convent
antibodi
use
model
base
transgen
rabbit
could
costeffect
produc
defucosyl
antibodi
interestingli
fucos
residu
identifi
recombin
human
isol
milk
transgen
rabbit
suggest
absenc
activ
fucosyl
rabbit
mammari
gland
thu
transgen
rabbit
becom
attract
model
product
new
class
highli
activ
antibodi
largescal
project
obtain
mab
ta
initi
late
genzym
transgen
compani
current
known
gtc
biotherapeut
sign
contract
larg
number
compani
develop
mab
therapeut
agent
initi
stage
mab
obtain
transgen
mice
order
assess
overal
activ
level
express
biolog
activ
mab
transgen
mice
compar
expect
valu
goatsproduc
creat
second
stage
gtc
biotherapeut
current
develop
technolog
product
sever
wide
use
mab
rituximab
herceptin
humira
erbitux
transgen
goat
work
aim
produc
rp
transgen
goat
activ
conduct
china
new
zealand
moment
fda
near
approv
salmon
express
growth
hormon
commerci
use
aquadvantag
accord
find
safe
human
environ
econom
impact
case
transgen
salmon
associ
almost
twofold
increas
growth
significantli
reduc
cost
cultiv
therefor
assum
near
futur
permiss
commerci
applic
variou
ta
obtain
ta
use
achiev
import
object
produc
modifi
milk
contain
human
rp
alter
composit
milk
increas
effici
dairi
product
product
improv
characterist
farm
anim
fast
growth
recycl
improv
resist
farm
anim
bacteri
viral
prion
infect
issu
artifici
infant
feed
nutrit
newborn
gain
import
term
composit
breast
milk
significantli
differ
goat
cow
milk
thu
human
milk
contain
much
higher
concentr
lactoferrin
mgml
lysozym
mgml
lactalbumin
mgml
protein
protect
organ
infect
improv
structur
intestin
epithelium
posit
effect
intestin
microflora
enhanc
immun
meanwhil
concentr
protein
significantli
lower
cow
milk
mgml
lactoferrin
mgml
lysozym
mgml
lactalbumin
mixtur
artifici
feed
produc
use
anim
milk
provid
optim
infant
nutrit
sinc
prepar
hydrolys
contain
function
protein
transgen
cow
express
recombin
lactoferrin
mgml
lysozym
mgml
human
lactalbumin
mgml
obtain
china
produc
modifi
milk
milk
contain
three
human
rp
optim
concentr
intend
product
next
transgen
goat
whose
milk
contain
recombin
human
lysozym
concentr
mgml
correspond
lysozym
concentr
breast
milk
obtain
usa
demonstr
pasteur
milk
human
lysozym
posit
effect
health
young
goat
pig
univers
california
davi
usa
institut
biomedicin
feder
univers
brazil
receiv
grant
govern
brazil
explor
possibl
use
milk
contain
recombin
human
lysozym
treat
diarrhea
children
lowincom
famili
product
transgen
goat
express
recombin
lactoferrin
milk
subsequ
product
milk
simultan
contain
combin
two
human
protein
also
schedul
governmentown
agroresearch
compani
new
zealand
produc
transgen
cow
aim
increas
effici
chees
product
casein
valuabl
protein
compris
approxim
milk
protein
casein
fraction
cow
milk
consist
kcasein
encod
singl
copi
gene
casein
aggreg
larg
micel
micellar
structur
stabil
may
vari
depend
ratio
casein
affect
physic
chemic
properti
milk
chees
made
via
aggreg
casein
micel
retain
water
fat
form
protein
network
increas
content
kcasein
lead
reduct
micellar
size
increas
thermal
stabil
necessari
chees
product
order
increas
amount
kcasein
milk
transgen
cow
addit
copi
gene
produc
endogen
gene
cow
regulatori
sequenc
use
sinc
kcasein
gene
character
rel
low
express
level
chimer
gene
contain
regulatori
region
gene
code
region
kcasein
use
product
transgen
cow
transgen
cow
eventu
produc
milk
character
increas
level
express
twofold
increas
kcasein
synthesi
result
clearli
demonstr
fact
milk
content
alter
transgenesi
increas
effici
multibilliondollar
chees
product
industri
one
problem
swine
breed
high
mortal
piglet
attribut
insuffici
content
milk
order
tackl
problem
produc
transgen
pig
gene
cow
insert
genom
result
increas
lactos
concentr
milk
significantli
decreas
mortal
rate
among
piglet
fed
modifi
milk
anoth
problem
swine
breed
pollut
environ
fece
contain
high
level
phosphoru
problem
resolv
produc
transgen
pig
whose
genom
contain
insert
phytaseencod
gene
bacteri
origin
result
level
phosphat
fece
transgen
pig
decreas
resist
diseas
anoth
extrem
import
aspect
applic
transgenesi
agricultur
thu
loss
inflict
mastiti
inflamm
mammari
gland
caus
bacteri
infect
cattl
exceed
billion
dollar
year
usa
alon
mastiti
typic
caus
staphylococci
lysostaphin
power
peptidoglycan
hydrolas
secret
staphylococcu
simulan
exhibit
bactericid
effect
staphylococci
caus
mastiti
transgen
cow
whose
milk
contain
lysostaphin
concentr
mgml
obtain
demonstr
cow
character
increas
resist
staphylococc
infect
bovin
spongiform
encephalopathi
bse
also
known
mad
cow
diseas
lethal
diseas
affect
cattl
countri
northern
hemispher
remov
prion
protein
gene
caus
diseas
propos
way
combat
result
transgen
cow
lack
gene
thu
resist
bse
produc
obviou
use
cow
reduc
incid
spread
diseas
epidem
exampl
demonstr
use
ta
agricultur
highli
promis
main
restrict
widespread
distribut
ta
fear
wider
public
regard
safeti
transgen
food
product
stringent
regulatori
requir
impos
result
make
difficult
obtain
permiss
use
ta
current
edit
may
year
develop
fda
approv
procedur
consid
applic
use
ta
procedur
approv
new
product
simpler
develop
countri
govern
public
view
ta
one
review
way
resolv
problem
food
secur
improv
live
standard
result
project
applic
ta
agricultur
current
implement
countri
brazil
argentina
china
conclus
effici
method
produc
ta
express
rp
develop
past
year
ta
offer
opportun
significantli
reduc
cost
produc
mab
human
rp
posttransl
modif
close
match
human
protein
recent
main
reason
behind
reluct
produc
rp
use
ta
develop
countri
includ
lack
develop
law
regul
use
ta
strict
ethic
standard
protest
public
use
anim
bioreactor
howev
situat
begun
chang
detail
regul
accompani
use
ta
product
rp
develop
establish
two
manufactur
product
rp
milk
ta
approv
regulatori
agenc
usa
eu
remov
mani
issu
relat
organ
product
expir
patent
mani
biolog
prepar
increas
competit
manufactur
forc
compani
search
econom
effici
technolog
model
product
thu
like
near
futur
use
ta
biotechnolog
food
industri
expand
work
support
feder
target
contract
